Vertex Pharmaceuticals (VRTX) Research & Development (2009 - 2026)

Vertex Pharmaceuticals (VRTX) has reported Research & Development for 18 consecutive years, with $961.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 1.85% year-over-year to $961.6 million; the TTM figure through Mar 2026 stood at $3.9 billion (up 1.85% YoY), while the FY2025 annual figure was $3.9 billion, up 7.69% from the prior year.
• Research & Development came in at $961.6 million for Q1 2026 at Vertex Pharmaceuticals, down from $973.7 million in the prior quarter.
• The five-year high for Research & Development was $998.7 million in Q4 2024, with the low at $600.1 million in Q2 2022.
• Average Research & Development over 5 years is $835.6 million, with a median of $824.6 million recorded in 2023.
• Across the five-year window, Research & Development soared 38.12% in 2022 and declined 2.5% in 2025, its largest moves.
• Year by year, Research & Development stood at $694.1 million in 2022, then rose by 18.8% to $824.6 million in 2023, then grew by 21.11% to $998.7 million in 2024, then retreated by 2.5% to $973.7 million in 2025, then decreased by 1.24% to $961.6 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $961.6 million, $973.7 million, and $977.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.